• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Pluristem Therapeutics Inc.

    1/26/22 1:52:20 PM ET
    $PSTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PSTI alert in real time by email
    SC 13G 1 ea154519-13gslager_pluristem.htm SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.   )*

     

    PLURISTEM THERAPEUTICS INC.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    72940R300

    (CUSIP Number)

     

    January 24, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐  Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 72940R30013GPage 2 of 9 Pages

     

    1.

    Names of Reporting Persons

    Regals Capital Management LP

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    1,071,938

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    1,071,938

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,071,938

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

     

    ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    3.34%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

    CUSIP No. 72940R30013GPage 3 of 9 Pages

     

    1.

    Names of Reporting Persons

    Regals Fund LP

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    1,071,938

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    1,071,938

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,071,938

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

     

    ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    3.34%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

    CUSIP No. 72940R30013GPage 4 of 9 Pages

     

    1.

    Names of Reporting Persons

    David M. Slager

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Dutch

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    613,100

     

    6.

    Shared Voting Power

     

    1,071,938

     

    7.

    Sole Dispositive Power

     

    613,100

     

    8.

    Shared Dispositive Power

     

    1,071,938

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,685,038

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

     

    ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.25%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

    CUSIP No. 72940R30013GPage 5 of 9 Pages

     

    Item 1(a).Name of Issuer

     

    Pluristem Therapeutics Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices

     

    MATAM Advanced Technology Park, Building No. 5 Haifa, Israel 3508409.

     

    Item 2(a).Name of Person Filing

     

    This Schedule is filed on behalf of each of the following Reporting Persons:

     

    (1) Regals Capital Management LP (“Regals Management”)

     

    (2) Regals Fund LP (“Regals Fund”)

     

    (3) David M. Slager (“Mr. Slager”)

     

    Item 2(b).Address of Principal Business Offices or, if None, Residence

     

    The address of each Reporting Person is:

     

    c/o Regals Capital Management LP
    152 West 57th Street, 9th Floor
    New York, NY 10019

     

    Item 2(c).Citizenship

     

    Each of Regals Management and Regals Fund is a Delaware limited partnership.

     

    Slager is a citizen of The Netherlands.

     

    Item 2(d).Title of Class of Securities

     

    Common Stock.

     

    Item 2(e).CUSIP Number

     

    72940R300

     

    Item 3.If the statement is being filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the filing person is a:

     

    Not Applicable

     

    (a) ☐  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

     

    CUSIP No. 72940R30013GPage 6 of 9 Pages

     

    (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________________________________________________________________________

     

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of the date hereof, Regals Fund directly owned 1,071,938 shares of Common Stock. Regals Management, as the investment manager of Regals Fund, may be deemed to beneficially own the shares of Common Stock owned directly by Regals Fund. Mr. Slager, as the managing member of the general partner of Regals Management, may be deemed to beneficially own the shares of Common Stock beneficially owned by Regals Management, in addition to the 613,100 shares of Common Stock he owns directly

     

    (b)Percent of class:

     

    The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 32,099,615 shares of Common Stock outstanding as of September 30, 2021, which is the total number of shares of Common Stock outstanding as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 8, 2021. As of the date hereof, each of Regals Fund and Regals Management may be deemed to have beneficially owned approximately 3.34% of the shares of Common Stock outstanding and Mr. Slager may be deemed to beneficially have owned approximately 5.25% of the shares of Common Stock outstanding.

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Cover Pages Items 5-9

     

    (ii)Shared power to vote or to direct the vote:

     

    See Cover Pages Items 5-9

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9

     

     

    CUSIP No. 72940R30013GPage 7 of 9 Pages

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not Applicable

     

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10.Certification

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    CUSIP No. 72940R30013GPage 8 of 9 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each Reporting Person certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: January 26, 2022 Regals Capital Management LP
      By: Regals Capital Holdings LLC, its general partner
       
      /s/ David M. Slager
      Name: David M. Slager
      Title: Managing Member
       
    Dated: January 26, 2022 Regals Fund LP
      By: Regals Fund GP LLC, its general partner
       
      /s/ David M. Slager
      Name: David M. Slager
      Title: Managing Member
       
    Dated: January 26, 2022 David M. Slager
       
      /s/ David M. Slager
      Name: David M. Slager

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    CUSIP No. 72940R30013GPage 9 of 9 Pages

     

    EXHIBIT INDEX

     

    Exhibit  Description
        
    99.1  Agreement of Joint Filing. (Filed herewith)

     

     

     

     

    Get the next $PSTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PSTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Independence Realty Trust Appoints Craig Macnab to its Board of Directors

      Waives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,

      3/1/24 7:55:00 AM ET
      $AMT
      $IRT
      $NNN
      $VICI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

      HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company ("Pluristem"), and Tnuva Group ("Tnuva Group" or "Tnuva"), Israel's largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat. Eyal Rosenthal, Chief Executive Officer(photo credit: Jim Vetter) Mr. Rosenthal is a seasoned entrepreneur and visionary leader in the agritech and food tech industries, serving until recently as venture partner and head of Israeli operations at Finistere Ventures, a pioneering global ventu

      3/8/22 7:12:00 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

      HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University's School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market. Prof. Shalev has more than 30 years of experience working in clinical environments and research settings at the intersection of health and technology. She was the founder and Chief Executive Officer of the KSM Institute of Research and Innovation and Mac

      7/19/21 7:00:00 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Pluristem Therapeutics Inc.

      SC 13D - Pluri Inc. (0001158780) (Subject)

      1/4/23 4:17:53 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Pluristem Therapeutics Inc.

      SC 13G - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)

      1/26/22 1:52:20 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluristem Therapeutics, Inc. (Amendment)

      SC 13G/A - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)

      6/1/21 7:36:59 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Independence Realty Trust Appoints Craig Macnab to its Board of Directors

      Waives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,

      3/1/24 7:55:00 AM ET
      $AMT
      $IRT
      $NNN
      $VICI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri CEO Issues Shareholder Update

      HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Pluri: One simple, short word of Greek origin that encapsulates the strategic evolution for our Company. This is our new name. Today, I am proud to share the vision of Pluri: to help pioneer a biotech revolution to create a range of next-generation cell-based products that improve human wellbeing, increase sustainability, and advance solutions to humanity's greatest challenges. In early 2021,

      7/25/22 7:00:00 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

      As of July 26, 2022, Pluri's stock will trade under the symbol PLURThe new name reflects the Company's strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and sustainabilityVisit our new Company website: www.pluri-biotech.com HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company, today announced its name change (NASDAQ:PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harness

      7/25/22 1:00:00 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Yanay Yaky was granted 334,821 shares, increasing direct ownership by 23% to 1,760,125 units

      4 - Pluri Inc. (0001158780) (Issuer)

      12/22/22 8:56:45 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Aberman Zami sold $1,940 worth of shares (2,000 units at $0.97), decreasing direct ownership by 0.13% to 1,491,973 units

      4 - Pluri Inc. (0001158780) (Issuer)

      12/22/22 8:52:59 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Aberman Zami bought $145,109 worth of shares (80,616 units at $1.80)

      4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)

      2/14/22 4:00:49 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    SEC Filings

    See more
    • Pluristem Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Pluri Inc. (0001158780) (Filer)

      1/24/23 4:05:21 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form D filed by Pluristem Therapeutics Inc.

      D - Pluri Inc. (0001158780) (Filer)

      12/30/22 9:49:07 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluristem Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Pluri Inc. (0001158780) (Filer)

      12/28/22 4:01:52 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Pluristem Therapeutics with a new price target

      Alliance Global Partners initiated coverage of Pluristem Therapeutics with a rating of Buy and set a new price target of $12.50

      5/4/21 8:35:21 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care